Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Emtricitabine

FDA-approved product (capsule, oral), marketed as Emtricitabine, Emtriva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Emtricitabine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF09

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Emtricitabine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Emtricitabine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

    NCT00110305 · start 2005-06

    Registered record
    Registry ID
    NCT00110305
    Conditions
    Human Immunodeficiency Virus Type 1
    Interventions
    TMC278 25 mg; TMC278 75 mg; TMC278 150 mg; Efavirenz; Non-nucleoside reverse transcriptase inhibitor (NRTIs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-06
    Completion
    2011-12
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus Type 1
    InterventionTMC278 25 mg; TMC278 75 mg; TMC278 150 mg; Efavirenz +1 more
    PhasePhase 2
    Registry statusCompleted

  • "The Once A Day Protease Inhibitor Regimens"

    NCT00242216 · start 2004-05

    Registered record
    Registry ID
    NCT00242216
    Conditions
    HIV Infections
    Interventions
    ritonavir-boosted atazanavir; ritonavir-boosted fosamprenavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-05
    Completion
    2010-03
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionritonavir-boosted atazanavir; ritonavir-boosted fosamprenavir
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access

    NCT01003990 · start 2002-10

    Registered record
    Registry ID
    NCT01003990
    Conditions
    HIV
    Interventions
    Atazanavir; Atazanavir/Ritonavir; Tenofovir/Emtricitabine; Lopinavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-10
    Completion
    2016-02
    Enrolment
    710

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionAtazanavir; Atazanavir/Ritonavir; Tenofovir/Emtricitabine; Lopinavir/ritonavir
    PhasePhase 3
    Registry statusCompleted

  • Three Month Course of Anti-HIV Medications for People Recently Infected With HIV

    NCT00087464

    Registered record
    Registry ID
    NCT00087464
    Conditions
    HIV Infections
    Interventions
    Emtricitabine; Nevirapine; Tenofovir disoproxil fumarate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionEmtricitabine; Nevirapine; Tenofovir disoproxil fumarate
    PhaseNot applicable
    Registry statusWithdrawn